Thrivent Financial for Lutherans Has $16.37 Million Stock Holdings in Pfizer Inc. (NYSE:PFE)

Thrivent Financial for Lutherans trimmed its holdings in shares of Pfizer Inc. (NYSE:PFE) by 27.1% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 617,302 shares of the biopharmaceutical company’s stock after selling 229,280 shares during the period. Thrivent Financial for Lutherans’ holdings in Pfizer were worth $16,369,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently bought and sold shares of the company. Swedbank AB lifted its position in Pfizer by 0.7% in the 3rd quarter. Swedbank AB now owns 5,745,831 shares of the biopharmaceutical company’s stock worth $166,284,000 after buying an additional 37,636 shares in the last quarter. United Bank raised its holdings in shares of Pfizer by 3.7% during the third quarter. United Bank now owns 35,599 shares of the biopharmaceutical company’s stock worth $1,030,000 after acquiring an additional 1,277 shares in the last quarter. Segall Bryant & Hamill LLC acquired a new stake in Pfizer during the third quarter valued at $2,123,000. Connor Clark & Lunn Investment Management Ltd. grew its stake in Pfizer by 67.4% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 14,801 shares of the biopharmaceutical company’s stock valued at $428,000 after purchasing an additional 5,959 shares in the last quarter. Finally, Landscape Capital Management L.L.C. acquired a new position in Pfizer in the 3rd quarter worth about $1,319,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on PFE shares. Citigroup lowered their price target on Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a research note on Tuesday, January 28th. Truist Financial decreased their target price on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research report on Wednesday, December 18th. Hsbc Global Res upgraded shares of Pfizer to a “strong-buy” rating in a report on Monday, March 10th. UBS Group decreased their price objective on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a report on Wednesday, January 8th. Finally, Guggenheim restated a “buy” rating on shares of Pfizer in a report on Tuesday. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have issued a buy rating and three have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Pfizer has an average rating of “Moderate Buy” and an average price target of $31.92.

Pfizer Price Performance

Shares of Pfizer stock opened at $26.20 on Friday. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The company has a market cap of $148.61 billion, a PE ratio of 18.58, a price-to-earnings-growth ratio of 0.64 and a beta of 0.61. The firm has a fifty day moving average price of $26.17 and a two-hundred day moving average price of $27.05. Pfizer Inc. has a fifty-two week low of $24.48 and a fifty-two week high of $31.54.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating the consensus estimate of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm had revenue of $17.76 billion during the quarter, compared to analysts’ expectations of $17.26 billion. During the same quarter in the prior year, the firm posted $0.10 EPS. The company’s revenue for the quarter was up 24.7% on a year-over-year basis. Analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Insiders Place Their Bets

In other Pfizer news, Director Ronald E. Blaylock acquired 19,457 shares of Pfizer stock in a transaction dated Thursday, February 13th. The stock was bought at an average cost of $25.65 per share, with a total value of $499,072.05. Following the acquisition, the director now owns 27,707 shares of the company’s stock, valued at approximately $710,684.55. The trade was a 235.84 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 0.06% of the company’s stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.